Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)

NCT00184015 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Cancer

Interventions

DRUG: Bevacizumab and Bortezomib
DRUG: Bevacizumab and Bortezomib

Sponsor

University of Southern California